{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:29:17Z","timestamp":1782905357181,"version":"3.54.5"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clml.2022.10.009","type":"journal-article","created":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T01:20:02Z","timestamp":1666488002000},"page":"e27-e40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8395-9361","authenticated-orcid":false,"given":"Ademola S.","family":"Ojo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwasegun","family":"Akinyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojisola O.","family":"Araoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.10.009_bib0001","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.10.009_bib0002","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.10.009_bib0003","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","article-title":"Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations","volume":"28","author":"Blad\u00e9","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.10.009_bib0004","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.10.009_bib0005","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.009_bib0006","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.009_bib0007","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.10.009_bib0008","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/10428194.2019.1648802","article-title":"Burden of disease progression in patients with multiple myeloma in the US","volume":"61","author":"Hagiwara","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.10.009_bib0009","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3390\/cancers12051223","article-title":"Treatment of smoldering multiple myeloma: ready for prime time?","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2022.10.009_bib0010","first-page":"1","article-title":"The role of early intervention in high-risk smoldering myeloma","volume":"40","author":"Joseph","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2022.10.009_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.clml.2022.10.009_bib0012","series-title":"Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition","author":"Higgins","year":"2019"},{"key":"10.1016\/j.clml.2022.10.009_bib0013","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2022.10.009_bib0014","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.10.009_bib0015","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of Lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.10.009_bib0016","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.10.009_bib0017","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15384","article-title":"Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study","volume":"182","author":"Jagannath","year":"2018","journal-title":"Br J Haematol"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2022.10.009_bib0018","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1182\/blood-2019-123205","article-title":"A multicenter phase II single arm trial of Isatuximab in patients with high risk smoldering multiple myeloma (HRSMM)","volume":"134","author":"Manasanch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.009_bib0019","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of Siltuximab in high-risk smoldering multiple myeloma","volume":"25","author":"Brighton","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.10.009_bib0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/blood-2018-154","article-title":"Phase II trial of combination of Elotuzumab, Lenalidomide, and Dexamethasone in high-risk smoldering multiple myeloma","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.009_bib0021","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","article-title":"Lenalidomide, and Dexamethasone followed by Lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: a phase 2 nonrandomized controlled trial","volume":"7","author":"Kazandjian","year":"2021","journal-title":"JAMA Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.10.009_bib0022","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-99-117871","article-title":"Ghobrial; phase II trial of the combination of Ixazomib, Lenalidomide, and Dexamethasone in high-risk smoldering multiple myeloma","volume":"132","author":"Bustoros","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2022.10.009_bib0023","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2019-125204","article-title":"Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd","volume":"134","author":"Maria-Victoria","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.009_bib0024","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.009_bib0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - a randomized study","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.10.009_bib0026","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/bjc.1994.474","article-title":"Treatment of multiple myeloma according to the extension of the disease: a prospective, randomized study comparing a less with a more aggressive cystostatic policy. Cooperative group of study and treatment of multiple myeloma","volume":"70","author":"Riccardi","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2022.10.009_bib0027","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative group of study and treatment of multiple myeloma","volume":"82","author":"Riccardi","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2022.10.009_bib0028","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3109\/10428190309178778","article-title":"Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial","volume":"44","author":"Musto","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.10.009_bib0029","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"GIMEMA (Italian Group for Adult Hematologic Diseases)\/multiple myeloma working party and the Italian myeloma network. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.10.009_bib0030","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study","volume":"52","author":"D'Arena","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.10.009_bib0031","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.10.009_bib0032","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.10.009_bib0033","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.009_bib0034","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","author":"Witzig","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.10.009_bib0035","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.009_bib0036","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","article-title":"Multiple myeloma clonal evolution in homogeneously treated patients","volume":"32","author":"Corre","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.10.009_bib0037","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1182\/bloodadvances.2020001508","article-title":"Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma","volume":"4","author":"Alonso","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.10.009_bib0038","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.10.009_bib0039","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.10.009_bib0040","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.10.009_bib0041","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.10.009_bib0042","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.10.009_bib0043","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.009_bib0044","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2019-02-895193","article-title":"A phase 1b study of isatuximab plus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma","volume":"134","author":"Mikhael","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.009_bib0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"90","author":"Orlowski","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.10.009_bib0046","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdn018","article-title":"Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma","volume":"19","author":"Palumbo","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.10.009_bib0047","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2008.07303.x","article-title":"The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma","volume":"143","author":"Niesvizky","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.10.009_bib0048","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3324\/haematol.2009.015917","article-title":"Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma","volume":"95","author":"Harousseau","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.10.009_bib0049","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.10.009_bib0050","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3389\/fonc.2020.00860","article-title":"Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches","volume":"10","author":"Kostopoulos","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2022.10.009_bib0051","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.10.009_bib0052","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.10.009_bib0053","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2022.10.009_bib0054","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0169-5002(00)00179-3","article-title":"Quality of life in lung cancer patients: as an important prognostic factor","volume":"31","author":"Montazeri","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clml.2022.10.009_bib0055","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1186\/1471-2458-12-790","article-title":"Quality of life predicts survival in patients with non-small cell lung cancer","volume":"12","author":"Li","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.clml.2022.10.009_bib0056","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.3390\/ijerph17196938","article-title":"Quality of life of cancer patients treated with chemotherapy","volume":"17","author":"Lewandowska","year":"2020","journal-title":"Int J Environ Res Public Health"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:42Z","timestamp":1761871242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2152265022017098"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.10.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}